only to detect an increased incidence of rare tumor types, but also 48 to discriminate treatment-related effects from spontaneous, or 49 background, incidence of common tumor types. For this reason, 50 US (US EPA, 1998; FDA, 2006) and OECD (1995a) regulatory guide-51 lines for the conduct of carcinogenicity studies in rodents specify 52 the use of at least 50 animals per sex per treatment group. In addi-53 tion, OECD states that ''it is unlikely that a regulatory authority 54 would find a study using a lower core number of animals per sex 55 and per group acceptable for regulatory purposes, since a sufficient 56 number of animals should be used so that a thorough biological and 57 statistical evaluation can be carried out.'' (OECD, 1995b) . OECD fur-58 ther states that ''for strains with poor survival such as SD rats, high-59 er numbers of animals per group may be needed in order to 60 maximize the duration of treatment (typically at least 65/sex/ 61 group).'' (OECD, 1995b) . For this reason, the US EPA specifies that 62 survival in any group should not fall below 50% at 18 months or be-63 low 25% at 24 months (US EPA, 1998), while the US FDA specifies 64 survival of a minimum of 25 rats per sex per group at study termi-65 nation (FDA, 2006) . The SD rat has been widely used in toxicology 66 research, including numerous chronic studies, but these studies 67 employ many more animals than used by the authors in consider-68 ation of their lower survival rate and high background tumor rates, 69 especially mammary tumors in females. Doull et al., 2007) . There are numer- 76 ous problems in the way the data were statistically analyzed in this 77 study. 78 For example, in Table 3 , mean values are not presented for each 79 group and sex to allow comparison of measured parameters. Con-80 trol data are not presented. Instead, the authors used a statistical 81 method that is not traditionally used to present toxicology data, 82 a multivariate technique called Partial Least Squares Discriminant 83 Analysis (PLS-DA). Mean differences (%) of variables (discriminant 84 at 99% confidence intervals) were presented to investigate the rela-85 tionship among 48 blood and urine measurements relative to the 86 different treatment groups. PLS-DA can be used to identify patterns 87 in the data and to develop a function which can be used to discrim-88 inate between the groups. However, any differences between 89 groups must be further evaluated for toxicological relevance. 90 Presentation of the data in this manner does not lend itself to 91 straightforward interpretation of the study findings. 92 In Fig. 5 , the same PLS-DA procedures were followed with jack-93 knifed confidence intervals at 99% confidence level. This procedure 94 may be familiar to statisticians, but it is not commonly used to 95 present toxicology data and is difficult to interpret, particularly 96 when the data used to construct these graphs are not presented. 97 Examination of Fig. 5a would suggest that the majority of 98 measured parameters fall within 99% confidence intervals with 99 the exception of serum and urine electrolytes. Unfortunately, no 100 data were provided from other intervals when these data were 101 collected to determine if the same patterns were evident. No lab 102 historical data were provided to put these data in perspective. As 103 stated earlier, just because one can discriminate between the 104 groups, it does not make the result toxicologically relevant. There 105 was no presentation of actual statistical analysis to compare the 106 means for each measured parameter. 107 To determine if there are patterns of differences in toxicologi-108 cally related findings, the toxicologist expects to see the actual 109 mean data for each parameter/group and the standard deviation tained figures with graphs that were difficult to read because 119 lines overlapped, and percent variations were presented rather 120 than the mean test and control data which is the more standard 121 practice in presenting toxicology data. For instance, incidences of 122 1 vs. 2 or 5 vs. 10 both represent a change of 100%, however, these 123 absolute values would likely result in different conclusions. 124 The same criticism can be made for Fig. 2 and Table 2 where the 125 data are not broken out in the tables so the reader can actually see 126 what changes were observed for each group. The incomplete 127 presentation of study data, which was acknowledged by the 128 authors -''all data cannot be shown in one report, and the most 129 relevant are described here-'' precludes meaningful review and 130 evaluation of study results (Seralini et al., 2012). For example, his-131 topathology incidence/severity data are not presented (e.g., Table   132 2); nor is any laboratory historical control data provided to help Keenan, 1996) . Therefore, as discussed earlier, many more animals 189 than 10/sex/group would be needed to ensure that there would be in the study, and the other mammary and pituitary tumors ob-225 served in both control and treated female groups later in the study. 226 In Table 2 , the authors report that treated females had more mam-227 mary tumors/rat than controls. However, they do not follow the (Keenan, 1996) . 248 The authors reported treatment-related liver and kidney 249 pathologies in males. As evidence of kidney effects, they refer to 250 Table 2 where the incidence of chronic progressive nephropathy 251 (CPN) was 3/10 control animals compared to 7/10 animals in the 252 high dose NK603 group (non-sprayed). However, they neglect to 253 mention that the incidence of CPN in the NK603 sprayed groups 254 and the Roundup groups are similar and that the high dose groups 255 had the lowest incidence. They did not report the severity grades of 256 CPN to learn whether it was increased in a dose related manner. A 257 similar pattern was observed for liver findings, although Table 2   258 does not state what the liver pathologies were. This is an unaccept-259 able way to present pathology data. As the study progressed, there 260 were insufficient numbers of male animals left to make meaningful contained 50 rats/sex/group (Sakamoto et al., 2008) . 395 The authors also reported blood hormonal analyses (estradiol, In Table 1 , the study design represents that behavioral studies 530 were conducted twice. There is no mention of behavioral studies 531 in methods and no results were presented. 532 Ophthalmology was reported to be conducted twice. There is no 533 mention of ophthalmology evaluations in the methods and no 534 results were presented. 535 Microbiology was to be conducted in feces and urine. There is 536 no mention of microbiology evaluations in the methods and no 537 results were presented. 538 Evaluation of glyphosate residues in tissues was reported to be 539 performed, but no information on methods or data generated was Evaluation of the transgene in tissues was reported. There was 547 no mention of transgene analysis in methods or results sections, 548 with the exception of confirmation NK603 in maize grain and 549 formulated diets by qPCR. 550 Food, water consumption and body weights were reported to be 551 measured in the study, but the data were not presented in the 552 manuscript. This is basic information that should be provided for 553 a chronic feeding study to assess potential adverse effects. 554 Clinical pathology data was reported to be measured at eleven 555 different intervals during the study but only data from month 15 556 was summarized, and not in a manner it could be easily reviewed. 557 Further, data from the two sexes was presented differently. No 558 historical control information from the testing laboratory for 559 measured parameters was presented. 
